Patients with pre-existing hypertension, arrhythmias, or coronary artery disease face elevated risk and require specialist oversight if dual therapy is considered
It should also be noted that these trials predominantly included relatively healthy older participants, as individuals with potential comorbidities such as cardiovascular or renal diseases were often excluded [12, 34]
For long-term investors, this may mark the beginning of an exciting new phase in Indias pharma growth story
For semaglutide specifically, Wegovy starts at $499/month without insurance, while oral semaglutide (Rybelsus) starts at about $998/month
This cautious approach helps to minimize potential side effects while allowing you to find the optimal dose that works for you
According to FDA policy, licensed physicians may prescribe FDA-approved drugs for off-label uses based on medical judgment